Strategies for the management of insomnia: An update on pharmacologic therapies

Formulary

Volumn 42, Issue 2, 2007, Pages

  Nichols, Jake ^a,b,c   Alper, Caroline ^a   Milkin, Tamara ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOMIPRAMINE; DESIPRAMINE; DIPHENHYDRAMINE; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; IMIPRAMINE; MELATONIN RECEPTOR; NORTRIPTYLINE; QUAZEPAM; RAMELTEON; TEMAZEPAM; THEOPHYLLINE; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; ZALEPLON; ZOLPIDEM;

AMNESIA; BLURRED VISION; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONSERVATIVE TREATMENT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DEMENTIA; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FALLING; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEADACHE; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HEALTH STATUS; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYGIENE; INSOMNIA; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PREVALENCE; PRIAPISM; RANDOMIZED CONTROLLED TRIAL; RELAXATION TRAINING; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

EID: 33947169309     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. National Institutes of Health. NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2005;22:1-30.
2. The Gallup Organization for the National Sleep Foundation. Sleep in America: A National Survey of US Adults. Princeton, NJ: The Gallup Organization; 1995.
3. What is drowsy driving? National Sleep Foundation website. Available at: http://www.sleepfoundation.org/hottopics/index.php?secid=10&id=36. Accessed January 26, 2007.
4. National survey of distracted and drowsy driving attitudes and behaviors: 2002. US National Highway Traffic Safety Administration website. Available at: http://www.nhtsa.dot.gov/people/injury/drowsy_driving1/survey-distractive03/ drowsy.htm. Accessed January 26, 2007.
5. Kamel NS, Gammack JK. Insomnia in the elderly: Cause, approach, and treatment. Am J Med. 2006;119:463-469.
6. Buysse D, Bate G, Kirkpatrick P. Fresh from the pipeline: Ramelteon. Nat Rev Drug Discov. 2005;4:881-882.
7. Drugs and insomnia: The use of medications to promote sleep. NIH Consens Statement Online. 1983;4:1-19. Available at: http://consensus.nih. gov/1983/1983insomniadrugs039html.htm. Accessed January 18, 2007.
8. Chokroverty S. Patient information: Insomnia. UpToDate website. Available at: http://patients.uptodate.com/topic.asp?file=lung_dis/6505. Accessed January 18, 2007.
9. Sateia MJ, Pigeon WR. Identification and management of insomnia. Med Clin North Am. 2004;88:567-596, vii.
10. Chokroverty S. Diagnosis and treatment of sleep disorders caused by co-morbid disease. Neurology. 2000;54(5 suppl 1):S8-15.
11. Chesson A, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 2000;23:237-241.
12. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Arch Intern Med. 2004;164:1888-1896.
13. Treatment of insomnia. Treat Guidel Med Lett. 2006;42:5-10.
14. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep. 2003;26:177-182.
15. Chesson AL Jr, Anderson WM, Littner M, et al. Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 1999;22:1128-1133.
16. Hauri PJ, ed. Sleep hygiene, relaxation therapy, and cognitive interventions. In: Hauri PJ, ed. Case Studies in Insomnia. 1st ed. New York, NY: Springer; 1991:65-84.
17. Rybarczyk B, Stepanski E, Fogg L, Lopez M, Barry P, Davis A. A placebo-controlled test of cognitive-behavioral therapy for comorbid insomnia in older adults. J Consult Clin Psychol. 2005;73:1164-1174.
18. Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999;22:1134-1156.
19. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs. zopiclone for treatment of chronic primary insomnia in older adults: A randomized controlled trial. JAMA. 2006;295:2851-2858.
20. Currie SR, Wilson KG, Pontefract AJ, deLaplante L. Cognitive-behavioral treatment of insomnia secondary to chronic pain. J Consult Clin Psychol. 2000;68:407-416.
21. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial. JAMA. 1999;281:991-999.
22. Rybarczyk B, Lopez M, Benson R, Alsten C, Stepanski E. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging. 2002;17:288-298.
23. Mendelson WB, Roth T, Cassella J, et al. The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev. 2004;8:7-17.
24. Rickels K, Morris RJ, Newman H, et al. Diphenhydramine in insomniac family practice patients: A double-blind study. J Clin Pharmacol. 1983;23:234-242.
25. Kudo Y, Kurihara M. Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: A double-blind study. J Clin Pharmacol. 1990;30:1041-1048.
26. Benca RM. Diagnosis and treatment of chronic insomnia: A review. Psychiatr Serv. 2005;56:332-343.
27. Ancoli-Israel S. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. J Clin Psychiatry. 2005;66(suppl 9):24-30.
28. Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161:2091-2097.
29. Erman MK. Therapeutic options in the treatment of insomnia. J Clin Psychiatry. 2005;66(suppl 9):18-23.
30. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005;20:533-559.
31. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia related to dysthymia: Polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology. 2001;44:139-149.
32. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: Differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:249-260.
33. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol. 1998;13:191-198.
34. Schwartz T, Nihalani N, Virk S, et al. A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia. [abstract]. Int J Psychiatr Nurs Res. 2004;10:1146-1150.
35. Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16:139-144.
36. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 2000;14:3-20.
37. Morin AK, Jarvis CI, Lynch AM. Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy. 2007;27:89-110.
38. Silber MH. Clinical practice. Chronic insomnia. N Engl J Med. 2005;353:803-810.
39. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32:680-691.
40. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162:225-233.
41. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA. 1997;278:2170-2177.
42. Lunesta [package insert]. Marlborough, MA: Sepracor; 2005.
43. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20:1979-1991.
44. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26:793-799.
45. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487-495.
46. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28:720-727.
47. Ambien CR [package insert]. New York, NY: Sanofi-Synthelabo; 2005.
48. Soubrane C, Walsh J, Roth T. Efficacy and safety of a modified release formulation of zolpidem in adults. Presented at: the 158th Annual Meeting of the American Psychiatric Association; May 2126, 2005; Atlanta, Ga. Poster NR 582.
49. Roehrs T, Soubrane C, Walsh J, Roth T. Efficacy and safety of 6.25 mg of zolpidem modified-release formulation in elderly patients with primary insomnia. Presented at: the 158th Annual Meeting of the American Psychiatric Association; May 2126, 2005; Atlanta, Ga. Poster NR 586.
50. Rozerem [package insert]. Lincolnshire, IL. Takeda Pharmaceutical Company; 2005.
51. Zammit G, Roth T, Erman M, Sainati S, Weigand S, Zhang J. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia [abstract]. Sleep. 2005;28:A229. Abstract 0680.
52. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28:303-307.
53. Roth T, Seiden D, Sainati S, et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc. 2005;53(suppl 4):S25.
54. 2006 Redbook: Pharmacy's Fundamental Reference. Rev Ed ed. Montvale, NJ: Thompson PDR; 2006.
55. Gyllenhaal C, Merrirt SL, Peterson SD, Block KI, Gochenour T. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev. 2000;4:229-251.
56. McCall WV. Diagnosis and management of insomnia in older people. J Am Geriatr Soc. 2005;53(7 suppl):S272-277.